Show simple item record

dc.contributor.authorEllison, G
dc.contributor.authorAhdesmaki, M
dc.contributor.authorLuke, S
dc.contributor.authorWaring, PM
dc.contributor.authorWallace, A
dc.contributor.authorWright, R
dc.contributor.authorRothlisberger, B
dc.contributor.authorLudin, K
dc.contributor.authorMerkelbach-Bruse, S
dc.contributor.authorHeydt, C
dc.contributor.authorLigtenberg, MJL
dc.contributor.authorMensenkamp, AR
dc.contributor.authorde Castro, DG
dc.contributor.authorJones, T
dc.contributor.authorVivancos, A
dc.contributor.authorKondrashova, O
dc.contributor.authorPauwels, P
dc.contributor.authorWeyn, C
dc.contributor.authorHahnen, E
dc.contributor.authorHauke, J
dc.contributor.authorSoong, R
dc.contributor.authorLai, Z
dc.contributor.authorDougherty, B
dc.contributor.authorCarr, TH
dc.contributor.authorJohnson, J
dc.contributor.authorMills, J
dc.contributor.authorBarrett, JC
dc.date.accessioned2020-12-18T02:41:14Z
dc.date.available2020-12-18T02:41:14Z
dc.date.issued2018-03-01
dc.identifier.citationEllison, G., Ahdesmaki, M., Luke, S., Waring, P. M., Wallace, A., Wright, R., Rothlisberger, B., Ludin, K., Merkelbach-Bruse, S., Heydt, C., Ligtenberg, M. J. L., Mensenkamp, A. R., de Castro, D. G., Jones, T., Vivancos, A., Kondrashova, O., Pauwels, P., Weyn, C., Hahnen, E. ,... Barrett, J. C. (2018). An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. HUMAN MUTATION, 39 (3), pp.394-405. https://doi.org/10.1002/humu.23375.
dc.identifier.issn1059-7794
dc.identifier.urihttp://hdl.handle.net/11343/255454
dc.description.abstractOvarian cancer patients with germline or somatic pathogenic variants benefit from treatment with poly ADP ribose polymerase (PARP) inhibitors. Tumor BRCA1/2 testing is more challenging than germline testing as the majority of samples are formalin-fixed paraffin embedded (FFPE), the tumor genome is complex, and the allelic fraction of somatic variants can be low. We collaborated with 10 laboratories testing BRCA1/2 in tumors to compare different approaches to identify clinically important variants within FFPE tumor DNA samples. This was not a proficiency study but an inter-laboratory comparison to identify common issues. Each laboratory received the same tumor DNA samples ranging in genotype, quantity, quality, and variant allele frequency (VAF). Each laboratory performed their preferred next-generation sequencing method to report on the variants. No false positive results were reported in this small study and the majority of methods detected the low VAF variants. A number of variants were not detected due to the bioinformatics analysis, variant classification, or insufficient DNA. The use of hybridization capture or short amplicon methods are recommended based on a bioinformatic assessment of the data. The study highlights the importance of establishing standards and standardization for tBRCA testing particularly when the test results dictate clinical decisions regarding life extending therapies.
dc.languageEnglish
dc.publisherWILEY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleAn evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice
dc.typeJournal Article
dc.identifier.doi10.1002/humu.23375
melbourne.affiliation.departmentClinical Pathology
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.source.titleHuman Mutation
melbourne.source.volume39
melbourne.source.issue3
melbourne.source.pages394-405
dc.rights.licenseCC BY
melbourne.elementsid1285668
melbourne.contributor.authorWaring, Paul
melbourne.contributor.authorKondrashova, Olga
dc.identifier.eissn1098-1004
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record